In Brief: Medtronic InSync
This article was originally published in The Gray Sheet
Executive Summary
Medtronic InSync: Bi-ventricular cardiac stimulator for treament of congestive heart failure is "moving into the clinical trial phase in the U.S.," company Chairman and CEO William George tells investors at a Feb. 3 session of the Piper Jaffray medical device conference in New York City. The device, which paces both sides of the heart through a proprietary transvenous lead system, "is progressing quickly through its initial 60-patient human clinical in Europe as well as in Canada," George notes, adding that "the greatest long-term opportunity for Medtronic in the pacing business is the treatment of congestive heart failure with biventricular cardiac stimulation" technology...